3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
7
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
2
Conditions
Venous Thromboembolism
5
Neoplasms
4
Pulmonary Embolism
3
Venous Thrombosis
2
Thrombosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma
1
Embolism
1
Interventions
Dalteparin
3
apixaban
2
abelacimab
2
MAA868
2
isoquercitrin
1
edoxaban
1
calcium heparin
1
bemiparin
1
Tinzaparin
1
Rivaroxaban
1
Nadroparin
1
Heparin, Low-Molecular-Weight
1
Heparin
1
Fondaparinux
1
Enoxaparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Venous Thrombosis
×
apixaban
×
Clear all
NCT07493304
2026-05-29
ROXI-CAT-II
Regeneron Pharmaceuticals
Phase 3
Recruiting
1,600 enrolled
NCT05171049
2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3
Terminated
1,150 enrolled